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Objective. This study describes the long-term results of endoluminal therapy for iliac in-stent obstructions.
Design. This is a retrospective study.
Materials and methods. From 1992 to 2005, 68 patients (22 women), with a mean age of 6113 years and 16 bi-iliac
in-stent obstructions, underwent 84 endovascular interventions for focal iliac in-stent stenoses (n¼ 61) or occlusions
(n¼ 23). Primarily, only uncovered stents were placed. All patients were symptomatic: 70% had disabling intermittent
claudication, 23% had resting pain, and 7% had trophic changes. All had in-stent diameter reduction exceeding 50%
that was confirmed by duplex scanning and angiography. Procedures were performed under local anesthesia via the femoral
route.
Results. All interventions were initially technically successful, with a minor complication of pneumonia in one patient
(2%). Initial clinical success was achieved in 86% of patients. PTA alone was used to treat 72 (86%) in-stent obstructions,
the other 12 (14%) had PTA and renewed stent placement. The 30-day mortality rate was 0%. Mean follow-up was 35
months (range, 3 months to 10 years) and included duplex scanning. Primary clinical patency was 88% at 1 year,
62% at 3 years, and 38% at 5 years follow-up. During follow-up, 28 (33%) of 84 extremities required secondary reinter-
ventions because of symptomatic renewed in-stent stenosis, and 11 were treated successfully with repeated endovascular
interventions. Secondary patency at 1 year was 94%, 78% at 3 years, and 63% at 5 years. Surgical intervention was even-
tually needed in 17 (20%) of the 84 extremities.
Conclusions. Endoluminal therapy for iliac focal in-stent obstructive disease seems to be a safe technique with acceptable
long-term outcome and therefore a true alternative to primary surgical reconstruction.
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During the past decades, a major shift has occurred in
the treatment of obstructive iliac disease from open
reconstructions (desobstruction or bypass surgery) to
endovascular techniques. The surplus value of addi-
tional stents in iliac endoluminal therapy has been
studied thoroughly. Originally, additional stents were
indicated to treat periprocedural complications of per-
cutaneous transluminal angioplasty (PTA).1,2 Selective
use of stents was advocated in a later randomized
study, with similar outcome, and appeared to be
cost-effective compared with routine use of additional
*Corresponding author. J.P.P.M. de Vries, MD, PhD, Vascular Sur-
geon, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein,
The Netherlands.
E-mail addresses: j.vries@antonius.net, jppmdevries@planet.nl1078–5884/000634 + 05 $32.00/0  2006 Elsevier Ltd. All rights resstents.3 In daily practice, routine stent placement is
still attempted on a large scale to prevent recurrent
disease; however, the long-term outcome of iliac stent-
ing shows restenosis in up to 25%.4,5 Little is known so
far about the initial success and long-term outcome of
endovascular treatment of these iliac in-stent obstruc-
tions, which is the aim of this study.
Methods
Patients
Between January 1992 and July 2005, 1086 patients un-
derwent primary endoluminal treatment for aortoiliac
atherosclerotic obstructive disease in our hospital.
During this time, 129 patients were treated for symp-
tomatic iliac artery reobstructions, of which 45 ap-
peared after primary PTA alone or were locatederved.
635PTA for Iliac In-stent Stenosisoutside an iliac stent. The remaining 84 iliac reob-
structions were located in-stent and are the subject
of this study. Primarily, an uncovered stent was placed
in all patients.
Preprocedural evaluation included physical exami-
nation with additional ankle-brachial index (ABI)
measurement and duplex scanning. All patients un-
derwent digital subtraction angiography in at least
two planes to confirm the obstructive iliac in-stent le-
sion. Aspirin (80 mg daily) was given to all patients at
least 2 weeks before treatment of the in-stent obstruc-
tion and was continued for at least 3 months after the
procedure.
Methods
All procedures were performed under local anesthesia
in the angiography suite of the Interventional Radiol-
ogy Department. Angioplasty procedures were per-
formed by the three staff interventional radiologists,
with use of the Seldinger technique. For in-stent steno-
sis just distal to the aortic bifurcation, a bifemoral route
with ‘‘kissing balloon’’ technique was used; otherwise,
a single balloon was used. After crossing the in-stent
obstruction with a guidewire and subsequent PTA,
a control angiogram was obtained to measure the
trans-lesion pressure gradient. A persistent trans-
stenotic mean pressure gradient of 10 mm Hg or more
during pharmacologically induced vasodilatation was
an indication for selective renewed stent placement.
Other criteria for additional stent placement were
occlusive in-stent lesions, residual in-stent stenosis of
30% or more after PTA, or dissection. In case of renewed
stent placement, balloon-expandable stents (Palmaz,
Cordis, Johnson & Johnson, Warren, NJ) and self-
expendable stents (Wallstent; Boston Scientific,
Schneider, Bullach, Switzerland) were used. A bolus
of 5000 IU of heparin was given before angioplasty.
Most of the femoral access sites were closed with
a percutaneous femoral artery closure device. Patients
were discharged from the hospital on the first post-
operative day.
Follow-up
ABI at rest was measured before discharge. Postproce-
dural follow-up was at 3, 6, and 12 months, and yearly
thereafter. It consisted of clinical examination, ABI
measurements, and duplex scanning. In case of clinical
deterioration in combination with more than 50%
recurrent stenosis as measured by duplex scanning,
digital subtraction angiography was performed,
eventually in combination with reintervention.Definitions
Initial technical failure was defined as impossibility to
cross the in-stent obstruction or an angiographic re-
sidual stenosis exceeding 20%, with a mean pressure
gradient of more than 10 mm Hg across the treated
in-stent obstruction. During follow-up, primary and
secondary patency rates were defined according to
the standards for evaluating and reporting the results
of percutaneous interventions for peripheral arterial
disease.6 Clinical success was determined by using
the definitions of the Society for Vascular Surgery
(SVS) and the Interventional Society for Cardiovascu-
lar Surgery (ISCVS) (an upward shift by at least one
clinical category plus a change in ABI >0.10).7
Statistical analysis
Standard descriptive statistics were used. Patency
rates were computed using the Kaplan-Meier method
and compared with the log-rank test. For comparison
of means, the Student’s t test was used. The analysis
was performed using SAS 8.2 (SAS Inc., Cary, NC).
Results
During the study period, 68 patients (22 women), with
a mean age of 6113 years, underwent 84 endolumi-
nal interventions (16 bilateral obstructions) for symp-
tomatic iliac in-stent stenosis of at least 50% (n¼ 61)
or occlusion (n¼ 23). The in-stent obstructions were
located in the common iliac artery in 69% (n¼ 58),
and the remaining 31% were in the external iliac artery.
Indications for treatment of in-stent obstructions were
disabling intermittent claudication (SVS/ISCVS cate-
gory 2 and 3) in 70%, rest pain (category 4) in 23%,
and trophic changes (category 5) in 7%. Patient prepro-
cedural vascular risk factors are listed in Table 1. The
mean preprocedural ABI at rest was 0.68 0.26 and
0.53 .23 after exertion.
Table 1. Pre-procedural patient’s vascular risk factors
Risk factor Total
(n¼ 68) (%)
Coronary heart disease 22 (32)
Cerebrovascular accident 8 (12)
Hypertension 23 (34)
Hyperlipidemia 54 (79)
Renal insufficiency 2 (3)
Diabetes mellitus 18 (26)
Familiar history 30 (44)
Smoking 52 (76)Eur J Vasc Endovasc Surg Vol 32, December 2006
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cases, an illustrative example is shown in Fig. 1.
PTA alone was used to treat 72 (86%) in-stent ob-
structions, and 12 (14%) had PTA and renewed stent
placement. The complication rate was 2%, which
consisted of one patient with pneumonia. No in-
hospital deaths occurred, and the 30-day mortality
rate was 0%. The mean ABI at rest increased from
0.68 0.26 to 0.95 0.12 after the intervention
( p< 0.05). Clinical improvement for at least one
category according to the SCS-ISCVS criteria
occurred in 86% of patients. In 14% of patients, clin-
ical symptoms were unchanged after the procedure,
Fig. 1. Endoluminal treatment of severe iliac in-stent ob-
struction before (A) and after (B) angioplasty via transfe-
moral route.Eur J Vasc Endovasc Surg Vol 32, December 2006and no patients had clinical worsening. All patients
with unchanged clinical symptoms refused surgery
and were treated with continuation of a walking
program.
No patients were lost to follow-up. During a mean
follow-up of 35 months (range, 3 months to 10 years),
28 (33%) of 84 extremities required reintervention be-
cause of symptomatic renewed in-stent obstruction.
The mean interval before reintervention was 806
617 days. Multivariate analysis of risk factors revealed
that female gender, diabetes mellitus, renal insuffi-
ciency, renewed stent placement, and primary occlu-
sion were all not independent predictors for primary
patency failure rates.
Twelve of the 28 renewed obstructions during
follow-up were treated primarily with aortic-femoral
bypass grafting because of occlusions or at the pa-
tient’s request. Renewed endoluminal therapy was
used in 16 of the 28 extremities, of which 6 were suc-
cessfully treated with one renewed endovascular in-
tervention, and 5 patients eventually needed two
renewed endovascular interventions. Five of these
sixteen patients required surgical treatment because
of failure of renewed endoluminal attempts. Thus,
17 (20%) of 84 extremities eventually needed surgical
intervention.
The primary patency rates at 1, 3, and 5 years of
follow-up were 88%, 62%, and 38%, respectively
(Fig. 2), and secondary patency rates were 94%,
78%, 63%, respectively (Fig. 3). During follow-up, 6
patients died: 4 of myocardial failure, 1 of malig-
nancy, and 1 after surgical reconstruction for in-stent
reobstruction.
Fig. 2. Life table analysis of primary patency for endolumi-
nal treatment of iliac in-stent obstructions.
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Contrary to the abundance of reports focusing on
short-term and long-term results of primary PTA
with additional stent placement for iliac atheroscle-
rotic disease, less is known about the results of re-
peated endoluminal interventions in this area. To our
knowledge, ours is the first study in which follow-up
results of endovascular treatment for iliac in-stent
obstructions are presented. This is remarkable be-
cause in-stent stenosis is a common problem that
increases substantially with follow-up.8,9
Several causes for in-stent obstruction are reported,
and the most important might be induction of inflam-
matory infiltration by the stent itself, increased cell
replication in the inner intima, and accumulation of
extracellular matrix in the arterial wall.10,11 The best
treatment for in-stent obstruction in the iliac arteries
is still in its infancy, and most has to be learned
from coronary in-stent obstructions. Probably, the
use of cutting balloon angioplasty can be of benefit,
as it is in treating complex stenosis in the coronary ar-
teries.12 The cutting balloon catheter is equipped with
microtome-sharp atherotomes and is non-compliant
which makes it useful in severe in-stent stenosis.
Due to logistic reasons we didn’t use the cutting bal-
loon catheters in this series, but from January 2006
they are on the shelve and will be used in peripheral
in-stent obstructions. Standard application in primary
atherosclerotic peripheral lesions is still under discus-
sion. Recently, Ong et al.13 reviewed the current mo-
dalities to overcome coronary in-stent stenosis and
Fig. 3. Life table analysis of secondary patency for endolu-
minal treatment of iliac in-stent obstructions.concluded that brachytherapy is the only proven
tool so far, but it has several limitations, such as
high costs, requirement of specified training, and po-
tential adverse effects. Drug-eluting stents (DES)
might be of value, but randomized trials have to be
awaited.
Probably most useful in the treatment of in-stent
stenosis is to prevent it, which might be possible
with the use of DES. In coronary arteries, DES implan-
tation has led to significant reduction of in-stent
stenosis.14 In the iliac arteries, use of intravascular
ultrasound scanning at primary stent implantation
improved the adequacy of stent deployment and
therefore long-term patency of iliac stents.15 Other
possible solutions for reduction of in-stent stenosis
are the use of photodynamic therapy before stent
placement and insertion of the stents without previ-
ous balloon angioplasty to lessen intimal hyperpla-
sia.16,17 Again, thorough clinical trials are lacking.
We used standard endovascular treatments in our
retrospective series of 84 iliac in-stent obstructions.
Renewed stents were placed using selective criteria
(primary in-stent occlusion, in-stent residual stenosis
>30% after PTA, or dissection) similar to the criteria
for primary stent placement. In only 12 (14%) proce-
dures these criteria were met, and thus 12 renewed
stents were placed. This strategy seemed to be justi-
fied, because no difference in patency could be found
between the renewed stented group and non-stented
group. However, the retrospective character of this
study must be taken into account. Because no compar-
ative study to date has shown any specific stent to be
superior to another, the choice of Palmaz or Wallstent
depended on the personal preference of the interven-
tional radiologist. No major complications or proce-
durally related deaths occurred. This is of benefit
compared with the 30-day 3% to 4% mortality rate
with aortofemoral bypass surgery.18 Besides, even if
endoluminal therapy were to fail, the length and ex-
tent of the bypass graft would not be negatively influ-
enced because of the failure. Of the 28 extremities that
required reintervention during follow-up because of
symptomatic renewed in-stent obstructions, 12 were
abandoned from a repeated endovascular attempt
because of the length of the occlusion or patient
preference.
Symptomatic reobstruction occurred differently
during follow-up. The interval between endoluminal
treatment for in-stent obstruction and failure was
806 617 days. In general, no cutoff point could be
determined after which a stent was freed from re-
newed problems. In the patients who needed more
than one reintervention, the interval between inter-
ventions did not decrease.Eur J Vasc Endovasc Surg Vol 32, December 2006
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for primary failure rate, including female gender, dia-
betic mellitus, renal insufficiency, location of the stent,
and primary occlusion, was negative. Because of the
retrospective character of this study, another impor-
tant risk factor, occlusion of the ipsilateral superficial
femoral artery, could not be tested.
Conclusion
Endoluminal treatment of iliac in-stent obstructions is
a safe technique with good initial technical and clini-
cal success rates. At 5 years of follow-up, the primary
patency rate is 38%, and secondary patency is 63%.
Almost half of the failures can be successfully over-
come with renewed endovascular treatment. Peripro-
cedural complication and mortality rates are less
compared with surgical interventions, and therefore,
we think endoluminal therapy should be the treat-
ment of first choice.
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